MA41120A - Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci - Google Patents

Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Info

Publication number
MA41120A
MA41120A MA041120A MA41120A MA41120A MA 41120 A MA41120 A MA 41120A MA 041120 A MA041120 A MA 041120A MA 41120 A MA41120 A MA 41120A MA 41120 A MA41120 A MA 41120A
Authority
MA
Morocco
Prior art keywords
hepe
treating
methods
compositions including
preventing fibrosis
Prior art date
Application number
MA041120A
Other languages
English (en)
French (fr)
Inventor
John Climax
Kevin Duffy
Jonathan Rowe
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of MA41120A publication Critical patent/MA41120A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA041120A 2014-12-02 2015-12-01 Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci MA41120A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462086535P 2014-12-02 2014-12-02

Publications (1)

Publication Number Publication Date
MA41120A true MA41120A (fr) 2017-10-10

Family

ID=56092410

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041120A MA41120A (fr) 2014-12-02 2015-12-01 Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Country Status (17)

Country Link
US (1) US10363235B2 (cg-RX-API-DMAC7.html)
EP (2) EP3226873B1 (cg-RX-API-DMAC7.html)
JP (2) JP6986445B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170102879A (cg-RX-API-DMAC7.html)
CN (2) CN107206008A (cg-RX-API-DMAC7.html)
AU (2) AU2015358512B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017011685A2 (cg-RX-API-DMAC7.html)
CA (1) CA2968980A1 (cg-RX-API-DMAC7.html)
ES (1) ES2900593T3 (cg-RX-API-DMAC7.html)
IL (2) IL252431B (cg-RX-API-DMAC7.html)
MA (1) MA41120A (cg-RX-API-DMAC7.html)
MX (2) MX382116B (cg-RX-API-DMAC7.html)
PH (1) PH12017501022B1 (cg-RX-API-DMAC7.html)
RU (2) RU2020115523A (cg-RX-API-DMAC7.html)
SG (2) SG11201704495VA (cg-RX-API-DMAC7.html)
WO (1) WO2016090030A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201704463B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN105899485B (zh) 2013-11-15 2018-10-19 尊严科学有限公司 多不饱和羟基脂肪酸的药学上可接受的盐
RU2685706C2 (ru) * 2014-01-10 2019-04-23 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
JP2018502163A (ja) * 2015-01-16 2018-01-25 アフィミューン リミテッド １５−ｈｅｐｅを含む組成物及びそれを使用する方法
CN113896628A (zh) 2015-05-13 2022-01-07 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
CN108697680A (zh) 2015-12-18 2018-10-23 艾菲穆恩有限公司 包含15-hepe的组合物及其使用方法
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
WO2001049282A2 (en) * 2000-01-06 2001-07-12 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
EP1296923B3 (en) 2000-02-16 2012-04-11 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
ES2527438T3 (es) * 2006-08-08 2015-01-26 Metabolon, Inc. Marcadores de la hepatopatía grasa no alcohólica (NAFLD) y de la esteatohepatitis no alcohólica (NASH) y métodos de uso de los mismos
US8042070B2 (en) * 2007-10-23 2011-10-18 International Business Machines Corporation Methods and system for analysis and management of parametric yield
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
WO2012135032A2 (en) * 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) * 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
AU2012308491B2 (en) * 2011-09-16 2016-01-07 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2014530841A (ja) 2011-10-19 2014-11-20 ディグニティサイエンシスリミテッド Ｄｇｌａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法
BR112014013098A2 (pt) 2011-11-29 2017-06-13 Dignity Sciences Ltd composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos
US20150057216A1 (en) * 2011-12-16 2015-02-26 Tarix Pharmaceuticals Ltd. Angiotensins for treatment of fibrosis
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
PL2858496T3 (pl) 2012-05-10 2023-09-11 Solutex Na Llc Oleje o działaniu przeciwzapalnym zawierające naturalne wyspecjalizowane mediatory prorozdzielcze i ich prekursory
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
CN108697680A (zh) 2015-12-18 2018-10-23 艾菲穆恩有限公司 包含15-hepe的组合物及其使用方法

Also Published As

Publication number Publication date
US20160184252A1 (en) 2016-06-30
US10363235B2 (en) 2019-07-30
CN112245419A (zh) 2021-01-22
RU2017122758A (ru) 2019-01-09
AU2015358512A1 (en) 2017-07-20
EP3226873A1 (en) 2017-10-11
IL252431A0 (en) 2017-07-31
EP3988101A1 (en) 2022-04-27
SG11201704495VA (en) 2017-06-29
EP3226873A4 (en) 2018-08-08
AU2015358512B2 (en) 2021-02-18
SG10202010594WA (en) 2020-12-30
CN107206008A (zh) 2017-09-26
JP2022031813A (ja) 2022-02-22
ZA201804380B (en) 2021-03-31
MX2017007000A (es) 2017-12-07
PH12017501022A1 (en) 2017-11-27
JP2017536380A (ja) 2017-12-07
RU2721555C2 (ru) 2020-05-20
IL252431B (en) 2021-12-01
MX382116B (es) 2025-03-13
AU2021203189A1 (en) 2021-06-10
HK1245101A1 (zh) 2018-08-24
WO2016090030A1 (en) 2016-06-09
KR20170102879A (ko) 2017-09-12
ZA201704463B (en) 2018-11-28
EP3226873B1 (en) 2021-10-27
PH12017501022B1 (en) 2022-02-16
BR112017011685A2 (pt) 2018-01-02
CA2968980A1 (en) 2016-06-09
RU2017122758A3 (cg-RX-API-DMAC7.html) 2019-06-13
MX2021005080A (es) 2021-06-15
RU2020115523A (ru) 2021-01-27
JP6986445B2 (ja) 2021-12-22
ES2900593T3 (es) 2022-03-17
IL287983A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
EP3658612A4 (en) FORMATION OF PARTICLES WITH SUBSTANCES
EP3481434A4 (en) Crispr/cas9-based compositions and methods for treating retinal degenerations
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
MA45192A (fr) Traitement d'association
EP3344274A4 (en) METHOD AND COMPOSITIONS FOR TREATING DISEASES RELATED TO ABNORMAL INFLAMMATORY REACTIONS
ME03487B (me) Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti
EP3324978A4 (en) Oligonucleotide compositions and methods thereof
EP3328376A4 (en) Methods and compositions for treating metabolic reprogramming disorders
EP3353309A4 (en) COMPOSITIONS AND METHOD FOR GENERIC EDITING
EP3347469A4 (en) METHOD AND COMPOSITIONS FOR TREATING GLAUCOMA
EP3390634A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
EP3302379A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PTERYGIUM
MA41120A (fr) Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
EP3390642A4 (en) COMPOSITIONS AND METHODS OF TREATING RETINITIS PIGMENTOSA 18 AND RETINITIS PIGMENTOSA 13
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
EP3380095A4 (en) COMPOSITIONS AND METHODS FOR TREATING ISCHEMIC STROKE
EP3512524A4 (en) METHOD AND COMPOSITIONS FOR TREATING VIRUS INFECTIONS
EP3405191A4 (en) METHOD AND COMPOSITIONS FOR TREATING HYPERHIDROSIS
MA46750A (fr) Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
EP3317290A4 (en) COMPOSITIONS AND METHOD FOR TREATING VIRUS INFECTION
EP3368048A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSE
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
EP3522865A4 (en) METHOD AND COMPOSITIONS FOR TREATING STRIAE DISTENSAE
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique